Zealand Pharma A/S (Zealand Pharma A/S) Additional Paid-In Capital : $1,145.50 Mil(As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Additional Paid-In Capital?

Zealand Pharma A/S's quarterly additional paid-in capital increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($937.30 Mil) and increased from Dec. 2023 ($937.30 Mil) to Mar. 2024 ($1,145.50 Mil).

Zealand Pharma A/S's annual additional paid-in capital increased from Dec. 2021 ($645.85 Mil) to Dec. 2022 ($700.74 Mil) and increased from Dec. 2022 ($700.74 Mil) to Dec. 2023 ($937.30 Mil).

Zealand Pharma A/S Additional Paid-In Capital Historical Data

The historical data trend for Zealand Pharma A/S's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Additional Paid-In Capital Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

393.64

567.83

645.85

700.74

937.30

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	937.30	1,145.50

Zealand Pharma A/S Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zealand Pharma A/S Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.